- Home
- PBBK vs ICCM Comparison
PBBK vs ICCM Comparison
Compare PBBK & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PBBK | ICCM |
|---|---|---|
| Founded | 1919 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 43.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PBBK | ICCM |
|---|---|---|
| Price | $19.81 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 10.8K | ★ 382.4K |
| Earning Date | 02-25-2026 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.39 | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $13,918,000.00 | $2,975,000.00 |
| Revenue This Year | N/A | $13.67 |
| Revenue Next Year | N/A | $38.55 |
| P/E Ratio | $20.21 | ★ N/A |
| Revenue Growth | ★ 17.20 | N/A |
| 52 Week Low | $14.23 | $0.58 |
| 52 Week High | $22.92 | $1.66 |
Technical Indicators
Market Signals| Indicator | PBBK | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 57.06 |
| Support Level | $21.04 | $0.58 |
| Resistance Level | $21.95 | $0.68 |
| Average True Range (ATR) | 0.54 | 0.03 |
| MACD | -0.21 | 0.01 |
| Stochastic Oscillator | 9.43 | 98.44 |
Price Performance
Historical ComparisonAbout PBBK PB Bankshares Inc.
PB Bankshares Inc follows a community bank model and provides multiple services to individuals and small to midsize businesses. Its business consists of attracting retail and commercial deposits from the general public in its market area and investing those deposits, together with funds generated from operations and borrowings, in commercial real estate loans, commercial and industrial loans, construction, home equity lines of credit and to a lesser extent, one- to four-family residential real estate loans and consumer loans.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.